<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293630</url>
  </required_header>
  <id_info>
    <org_study_id>TCD11270</org_study_id>
    <secondary_id>U1111-1115-2568</secondary_id>
    <nct_id>NCT01293630</nct_id>
  </id_info>
  <brief_title>A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Paclitaxel and Carboplatin Every 3 Weeks in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the maximum tolerated dose (MTD) based on
      the incidence of dose limiting toxicity (DLT) and the maximum administered dose (MAD) of
      ombrabulin combined with paclitaxel and carboplatin administered every 3 weeks in patients
      with advanced solid tumors.

      Secondary Objectives:

        -  To assess the overall safety profiles of the combination therapy

        -  To characterize the pharmacokinetic profile of ombrabulin, its active metabolite RPR
           258063, paclitaxel, and carboplatin when used in combination

        -  To document the objective tumor response
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for each patient will include an up to 4-week screening phase,
      21-day study treatment cycles, an end of treatment visit and a follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of of drug related adverse events meeting the defined dose limiting toxicity at Cycle 1</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of treatment emergent adverse events</measure>
    <time_frame>30 days after the last injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of serious adverse events</measure>
    <time_frame>30 days after the last injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of laboratory abnormalities</measure>
    <time_frame>30 days after the last injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of ombrabulin: Cmax</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of RPR258063: tmax</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of paclitaxel: Cmax</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of carboplatin (free and total platinum): Cmax</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator determination of response</measure>
    <time_frame>30 days after the last injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of ombrabulin: AUC</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of ombrabulin: CL</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of ombrabulin: Vss</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of ombrabulin: t 1/2</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of RPR258063: Cmax</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of RPR258063: AUC</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of RPR258063: t 1/2</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of RPR258063: Metabolic Ratio</measure>
    <time_frame>Day 1-2 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of paclitaxel: AUC</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of paclitaxel: CL</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of paclitaxel: Vss</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of paclitaxel: t 1/2</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of carboplatin (free and total platinum): AUC</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of carboplatin (free and total platinum): CL</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of carboplatin (free and total platinum): Vss</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter of carboplatin (free and total platinum): t 1/2</measure>
    <time_frame>Day 1-3 at Cycle 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort - 1 through 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE8062 combined with paclitaxel and carboplatin will be administered once every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombrabulin (AVE8062)</intervention_name>
    <description>Pharmaceutical form:solution
Route of administration: intravenous</description>
    <arm_group_label>Cohort - 1 through 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Pharmaceutical form:solution
Route of administration: intravenous</description>
    <arm_group_label>Cohort - 1 through 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Pharmaceutical form:solution
Route of administration: intravenous</description>
    <arm_group_label>Cohort - 1 through 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with advanced solid tumor for which the combination paclitaxel and
             carboplatin is potentially effective such as lung cancer, epithelial ovarian cancer.

          -  Patients who have signed and dated an Institutional Review Board (IRB)-approved
             patient informed consent form prior to study enrollment or performance of any
             study-specific procedures.

        Exclusion criteria:

          -  Less than 20 or above 75 years of age ECOG performance status ≥2.

          -  Patients with more than 1 line of previous chemotherapy for advanced or metastatic
             disease (adjuvant/neoadjuvant and targeted agents [eg gefitinib] excluded)

          -  Concurrent treatment with any other anticancer therapy (except palliative
             radiotherapy),

          -  Women of childbearing potential who does not agree with contraception.

          -  Washout period of less than 28 days from prior anticancer therapies

          -  Symptomatic brain metastases and carcinomatous leptomeningitis.

          -  Other serious illness or medical conditions

          -  Current peripheral neuropathy ≥grade 2 and ototoxicity,

          -  Absolute neutrophils counts&lt;1.5 x 10E9/L. − Platelets count&lt;100 x 10E9/L. − hemoglobin
             &lt;9.0 g/dL (without red blood cell transfusion within 28 days before the test). −
             Creatinine Clearance&lt;55 mL/min. − Total bilirubin &gt;upper normal limits of the
             institutional norms. − ALT/AST &gt;1.5 times the upper normal limits of the institutional
             norms. − AP&gt;2.5 times the upper normal limits of the institutional norms.

          -  Medical history of myocardial infarction, angina pectoris, congestive heart failure,
             coronary artery bypass graft , arrhythmia , stroke or history of arterial or venous
             thrombo-embolism within the past 180 days requiring anticoagulants.

          -  Patient with a LVEF &lt;50% by echocardiography.

          -  Patient with uncontrolled hypertension and patient with organ damage related to
             hypertension such as left ventricular hypertrophy or grade 2 ocular fundoscopic
             changes or kidney impairment.

          -  Hypertension defined as systolic BP &gt;140 mmHg or diastolic BP &gt;90 mmHg on two repeated
             measurements at 30 minutes interval.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Akashi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Hidaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

